House of Representatives Committees

| House of Representatives Standing Committee on Health and Ageing

Footnotes

Chapter 1 Introduction

[1] AMI rejects this allegation, details of their response can be found in Submission No. 13, p 15.

[2] Andrology Australia viewed on 19 October 2009 at <http://www.andrologyaustralia.org/pageContent.asp?pageCode=ERECCAUSES>.

[3] Andrology Australia viewed on 19 October 2009 at <http://www.andrologyaustralia.org/pageContent.asp?pageCode=ERECFACTS>.

[4] Eli Lilly Australia, Submission No. 1, p 1.

[5] Marshall, V., Freemasons Foundation Centre for Men’s Health, Transcript, p 13.

[6] Eli Lilly Australia, Submission No. 1, p 1.

[7] Fitzsimons, M., Medicines Australia, Transcript, p 23; Marshall, V., Freemasons Foundation Centre for Men’s Health, Transcript, p 13; Doyle, R., Advanced Medical Institute, Transcript, p 28; The Royal Australasian College of Physicians, Submission No. 7, p 1; Pfizer Australia, Submission No. 11, p 2.

[8] Andrology Australia viewed on 19 October 2009 at <http://www.andrologyaustralia.org/pageContent.asp?pageCode=PREFACTS>.

[9] Andrology Australia viewed on 19 October 2009 at <http://www.andrologyaustralia.org/pageContent.asp?pageCode=PREFACTS>.

[10] Eli Lilly Australia, Submission No. 3, p 1.

[11] Andrology Australia viewed on 19 October 2009 at <http://www.andrologyaustralia.org/pageContent.asp?pageCode=ERECTREAT>.

[12] Doyle, R., Advanced Medical Institute (AMI), Transcript, p 3.

[13] AMI viewed on 19 October 2009 at <http://amiaustralia8-px.rtrk.com.au/page/
17/Treatment-Information>.

[14] AMI viewed on 19 October 2009 at <http://amiaustralia8-px.rtrk.com.au/page/4/Why-AMI>.

[15] See for example: Exhibit No. 15; Exhibit No. 39; Exhibit No. 44; Exhibit No. 45; Exhibit No. 46; Malouf, D., Urological Society of Australia and New Zealand (USANZ), Transcript, p 9.

[16] Doyle, R., AMI, Transcript, p 51.

[17] See Legal Aid Queensland, Submission No. 10.

Chapter 2 Issues and conclusions

[1] The National Preventative Health Taskforce viewed on 19 October 2009 at <http://www.preventativehealth.org.au/internet/preventativehealth/publishing.nsf/Content/national-preventative-health-strategy-1lp>.

[2] Marshall, V., Freemason’s Foundation Centre for Men’s Health, Transcript, p 13.

[3] Vartto, K., SHine SA, Transcript, p 16.

[4] Handlesman, D., Andrology Australia, Transcript, p 21.

[5] de Krester, D., et al, The Men in Australia Telephone Survey (MATeS) — lessons for all viewed on 19 October 2009 at <http://www.mja.com.au/public/issues/185_08_161006/dek10080_fm.html>.

[6] de Krester, D., et al, The Men in Australia Telephone Survey (MATeS) — lessons for all viewed on 19 October 2009 at <http://www.mja.com.au/public/issues/185_08_161006/dek10080_fm.html>.

[7] Doyle, R., Advanced Medical Institute (AMI), Transcript, p 26.

[8] McCann, B., Impotence Australia, Transcript, p 31.

[9] National Network of Libraries of Medicine viewed on 19 October 2009 at <http://nnlm.gov/outreach/consumer/hlthlit.html>.

[10] Pinskier, N., The Royal Australian College of General Practitioners (RACGP), Transcript, p 46.

[11] Marshall, V., The Freemasons Foundation Centre for Men’s Health, Transcript, p 29.

[12] de Krester, D., et al, The Men in Australia Telephone Survey (MATeS) — lessons for all viewed on 19 October 2009 at <http://www.mja.com.au/public/issues/185_08_161006/dek10080_fm.html>.

[13] de Krester, D., et al, The Men in Australia Telephone Survey (MATeS) — lessons for all viewed on 19 October 2009 at <http://www.mja.com.au/public/issues/185_08_161006/dek10080_fm.html>.

[14] Graduate Program in Sexual Health viewed on 19 October 2009 at <http://www.fhs.usyd.edu.au/sexual_health/about/index.shtml>.

[15] Weerakoon, P., University of Sydney, Transcript, p 16.

[16] Pinskier, N., RACGP, Transcript, p 37.

[17] Marshall, V., The Freemasons Foundation Centre for Men’s Health, Transcript, p 29.

[18] Doyle, R., AMI, Transcript, p 30.

[19] National Men’s Health Policy, viewed on 19 October 2009 at <http://www.health.gov.au/menshealthpolicy>.

[20] NSW Health viewed on 19 October 2009 at <http://www.chw.edu.au/parents/telehealth/nsw_health_consumer_telehealth_brochure.pdf>.

[21] Pinskier, N., RACGP, Transcript, p 46.

[22] Malouf, D., USANZ, Transcript, p 19; Fitzsimons, M., Medicines Australia, Transcript, p 23.

[23] See Handlesman, D., Andrology Australia, Transcript, p 34.

[24] Weerakoon, P., University of Sydney, Transcript, p 15.

[25] Doyle, R., AMI, Transcript, p 26. The AMI submission further details the benefits of technology based consultations. See Submission No. 13, p 4.

[26] Doyle, R., AMI, Transcript, p 34.

[27] Doyle, R., AMI, Transcript, p 34.

[28] AMI, Submission No. 13, p 5.

[29] Doyle, R., AMI, Transcript, p 27.

[30] Doyle, R., AMI, Transcript, p 28.

[31] Marshall, V., The Freemasons Foundation Centre for Men’s Health, Transcript, p 42.

[32] Doyle, R., AMI, Transcript, p 49.

[33] McMahon, C., The Royal Australasian College of Physicians, Transcript, p 45.

[34] New South Wales Medical Board, Exhibit No. 5.

[35] AMI, Submission No. 13, p 5.

[36] Doyle, R., AMI, Transcript, p 27.

[37] Malouf, D., USANZ, Transcript, p 18.

[38] Spierings, D., Impotence Australia, Transcript, p 14.

[39] AMI, Submission No. 13, p 8.

[40] Therapeutic Goods Administration (TGA) viewed on 19 October 2009 at <http://www.tga.gov.au/docs/html/tga/tgaginfo.htm>.

[41] Maskell-Knight, C., TGA, Transcript, p 3.

[42] TGA viewed on 19 October 2009 at <http://www.tga.gov.au/docs/html/tga/tgaginfo.htm>.

[43] Maskell-Knight, C., TGA, Transcript, p 4 and 8. See also Pinskier, N., RACGP, Transcript, p 8.

[44] Maskell-Knight, C., TGA, Transcript, p 8.

[45] Mackey, P., Pharmaceutical Society of Australia (PSA), Transcript, p 25.

[46] Mackey, P., PSA, Transcript, p 27.

[47] Doyle, R., AMI, Transcript, p 27. See also a number of supporting documents provided by AMI and accepted as Exhibits to the inquiry which are listed at Appendix C.

[48] Doyle, R., AMI, Transcript, p 54.

[49] See for example: Malouf, D., USANZ, Transcript, p 18 and Lording, D., Andrology Australia, Transcript, p 20.

[50] Maskell-Knight, C., TGA, Transcript, p 7.

[51] Australian Custom Pharmaceuticals, Submission No. 14, p 1.

[52] Malouf, D., USANZ, Transcript, p 40.

[53] Maskell-Knight, C., TGA, Transcript, p 5.

[54] Doyle, R., AMI, Transcript, p 28.

[55] AMI, Supplementary Submission No. 13.1, p 5.

[56] Doyle, R., AMI, Transcript, p 53.

[57] Further information about the review can be accessed from the TGA website at <http://www.tga.gov.au/meds/extempcomp2.htm>.

[58] Pinskier, N., RACGP, Transcript, p 23.

[59] Doyle, R., AMI, Transcript, p 27.

[60] Doyle, R., AMI, Transcript, p 27.